International
Ketamine could be a safe and effective treatment option for people with treatment-resistant bipolar depression, according to a small randomised controlled trial. To investigate the safety of the treatment for bipolar depression specifically, the researchers recruited 68 people with the condition and randomised them to receive ketamine treatment over two weeks, or treatment with a sedative called midazolam to act as a control. The researchers say at the end of the study, the ketamine group had lower overall depression symptoms and there was no evidence of safety issues such as psychosis or mania.
From:
Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression
In TRBD, adjunctive IV ketamine was well tolerated and associated with significant antidepressant effects compared to midazolam.
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
